Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

United We Stand: Regulatory Framework For Biosimilars May Bring Indian And MNCs Closer

This article was originally published in PharmAsia News

Executive Summary

HYDERABAD - Amid numerous fights over patents of leading drug brands, Indian and multinational drug companies may be seeing some sense in working cohesively to help the Indian government establish standard regulations and allow development and launch of future biosimilars and novel biotechnology-based drugs

You may also be interested in...



India’s Biosimilars Guidelines Lay Out Best Practices But Marketed Products Not To Be Reviewed – BIO Conference

The guidelines will enable a standardized biosimilars pathway as opposed to case-by-case application reviews

India’s Biosimilars Guidelines Lay Out Best Practices But Marketed Products Not To Be Reviewed – BIO Conference

The guidelines will enable a standardized biosimilars pathway as opposed to case-by-case application reviews

"We Want To Shape Up Medical Treatment Paradigm Through Partnerships," Says Merck Asia-Pac President Ramesh Subrahmanian: An Interview With PharmAsia News (Part 2 of 2)

Merck Asia Pacific President of Human Health Ramesh Subrahmanian has been among the most energetic executives to have worked in the Indian pharmaceutical industry. Prior to serving in his present responsibilities, Subrahmanian worked for Sanofi-Aventis in several senior capacities - one of which was to head the company's Indian operations in 2000.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC075982

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel